ALXO insider transaction filings
ALX ONCOLOGY HOLDINGS INC — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-18. Screen ALXO transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 3 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 3 legs across 3 filings by 2 insiders — 4,207 shares, $8,274 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.
- Largest priced transaction: sale of 2,230 shares @ $1.93 ($4,304) by Lettmann Jason, filed 2026-08-18.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Lettmann Jason — CHIEF EXECUTIVE OFFICER, Director | 1 | — | 1 leg · 2,230 sh · $4,304 | — |
| Wong Shelly — SVP, FINANCE AND CAO | 2 | — | 2 legs · 1,977 sh · $3,970 | — |
Recent Form 4 filings — ALX ONCOLOGY HOLDINGS INC
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-18 | 4 | Wong Shelly — SVP, FINANCE AND CAO | Sale (S): 573 @ $1.93 | EDGAR |
| 2026-08-18 | 4 | Lettmann Jason — CHIEF EXECUTIVE OFFICER, Director | Sale (S): 2,230 @ $1.93 | EDGAR |
| 2026-07-06 | 4 | Wong Shelly — SVP, FINANCE AND CAO | Sale (S): 1,404 @ $2.04 | EDGAR |
| 2026-04-17 | 4 | Knight Jeff E. — Chief Dev & Operating Officer | Grant/award (A): 800,000 (derivative) @ $0 | EDGAR |
| 2026-04-17 | 4 | Klencke Barbara — Chief Medical Officer | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2026-03-23 | 4 | Pinto Shelly — SVP, FINANCE AND CAO | Sale (S): 903 @ $2.17 | EDGAR |
| 2026-03-23 | 4 | Lettmann Jason — CHIEF EXECUTIVE OFFICER, Director | Sale (S): 12,311 @ $2.17 | EDGAR |
| 2026-03-05 | 4 | Klencke Barbara — Chief Medical Officer | Grant/award (A): 700,000 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | Pinto Shelly — SVP, FINANCE AND CAO | Sale (S): 565 @ $2.27 | EDGAR |
| 2026-02-19 | 4 | Lettmann Jason — CHIEF EXECUTIVE OFFICER, Director | Tax withholding (F): 2,201 @ $2.27 | EDGAR |
| 2026-02-04 | 4 | GOODMAN COREY S — Director, 10% owner | Purchase (P): 3,184,713 @ $1.57 | EDGAR |
| 2026-01-28 | 4 | Shantharam Harish — Chief Financial Officer | Grant/award (A): 303,000 (derivative) @ $0 | EDGAR |
| 2026-01-28 | 4 | Pinto Shelly — SVP, FINANCE AND CAO | Grant/award (A): 192,000 (derivative) @ $0 | EDGAR |
| 2026-01-28 | 4 | Lettmann Jason — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 912,000 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | Sandler Alan B. — Director | Grant/award (A): 10,100 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | Curran Daniel J. — Director | Grant/award (A): 16,833 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | Hemrajani Rekha — Director | Grant/award (A): 40,400 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | Takimoto Chris H — Director | Grant/award (A): 40,400 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | Garland J. Scott — Director | Grant/award (A): 40,400 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | GOODMAN COREY S — Director, 10% owner | Grant/award (A): 40,400 (derivative) @ $0 | EDGAR |
| 2026-01-07 | 4 | Pinto Shelly — SVP, FINANCE AND CAO | Sale (S): 3,925 @ $1.11 | EDGAR |
| 2025-10-16 | 4 | Pinto Shelly — SVP, FINANCE AND CAO | Grant/award (A): 140,000 (derivative) @ $0 | EDGAR |
| 2025-10-16 | 4 | Shantharam Harish — Chief Financial Officer | Grant/award (A): 198,750 (derivative) @ $0 | EDGAR |
| 2025-10-16 | 4 | Lettmann Jason — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 597,500 (derivative) @ $0 | EDGAR |
| 2025-09-19 | 4 | Klencke Barbara — Director | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2025-09-18 | 4 | Lettmann Jason — CHIEF EXECUTIVE OFFICER, Director | Purchase (P): 21,070 @ $1.07 · Purchase (P): 71,163 @ $1.08 | EDGAR |
| 2025-08-20 | 4 | Shantharam Harish — Chief Financial Officer | Purchase (P): 75,000 @ $0.78 | EDGAR |
| 2025-08-19 | 4 | Pinto Shelly — SVP, FINANCE AND CAO | Sale (S): 611 @ $0.64 | EDGAR |
| 2025-08-19 | 4 | Lettmann Jason — CHIEF EXECUTIVE OFFICER, Director | Sale (S): 2,382 @ $0.64 | EDGAR |
| 2025-08-13 | 4 | Curran Daniel J. — Director | Grant/award (A): 40,400 (derivative) @ $0 | EDGAR |
| 2025-07-08 | 4 | Pinto Shelly — SVP, FINANCE AND CAO | Sale (S): 2,011 @ $0.45 | EDGAR |
| 2025-07-01 | 4 | Pinto Shelly — SVP, FINANCE AND CAO | Sale (S): 1,532 @ $0.43 | EDGAR |
| 2025-04-15 | 4 | Pinto Shelly — SVP, FINANCE AND CAO | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2025-04-15 | 4 | Sandler Alan B. — Chief Medical Officer | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2025-04-15 | 4 | Shantharam Harish — Chief Financial Officer | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2025-04-15 | 4 | Lettmann Jason — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2025-03-18 | 4 | Pinto Shelly — SVP, FINANCE AND CAO | Grant/award (A): 3,000 @ $0 | EDGAR |
| 2025-03-18 | 4 | Lettmann Jason — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 42,000 @ $0 | EDGAR |
| 2025-02-21 | 4 | Pinto Shelly — SVP, FINANCE AND CAO | Sale (S): 550 @ $1.15 | EDGAR |
| 2025-02-21 | 4 | Pons Jaume — PRESIDENT & CSO | Sale (S): 1,326 @ $1.15 | EDGAR |
| 2025-02-21 | 4 | Lettmann Jason — CHIEF EXECUTIVE OFFICER, Director | Sale (S): 2,159 @ $1.15 | EDGAR |
| 2025-01-23 | 4 | Hemrajani Rekha — Director | Grant/award (A): 40,400 (derivative) @ $0 | EDGAR |
| 2025-01-23 | 4 | GOODMAN COREY S — Director, 10% owner | Grant/award (A): 40,400 (derivative) @ $0 | EDGAR |
| 2025-01-23 | 4 | Shantharam Harish — Chief Financial Officer | Grant/award (A): 600,000 (derivative) @ $0 | EDGAR |
| 2025-01-23 | 4 | Takimoto Chris H — Director | Grant/award (A): 40,400 (derivative) @ $0 | EDGAR |
| 2025-01-23 | 4 | Klencke Barbara — Director | Grant/award (A): 40,400 (derivative) @ $0 | EDGAR |
| 2025-01-08 | 4 | Pinto Shelly — Interim CFO | Sale (S): 2,221 @ $1.80 | EDGAR |
| 2025-01-02 | 4 | Pinto Shelly — Interim CFO | Sale (S): 1,426 @ $1.58 | EDGAR |
| 2025-01-02 | 4 | Pons Jaume — PRESIDENT & CSO | Sale (S): 10,796 @ $1.58 | EDGAR |
| 2024-12-04 | 4 | Lettmann Jason — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — ALX ONCOLOGY HOLDINGS INC
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-30 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-26 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-11 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-08 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-13 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-27 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-30 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-30 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-21 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ALXO returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →